Gustavo E. Velásquez, MD, MPH is an Assistant Adjunct Professor in the Division of HIV, Infectious Diseases, and Global Medicine at the University of California, San Francisco. He is an infectious disease physician and clinical researcher whose main research interest is the development of novel treatment regimens for drug-susceptible and drug-resistant tuberculosis (TB), with special interests in the safety and tolerability of TB treatment and management of TB/HIV co-infection. He works with the endTB consortium (www.endTB.org) and serves as a co-investigator in two multi-country Phase 3 randomized controlled clinical trials evaluating novel shortened oral regimens for multidrug-resistant tuberculosis (MDR-TB), specifically fluoroquinolone-susceptible MDR-TB (endTB, NCT02754765) and fluoroquinolone-resistant MDR-TB (endTB-Q, NCT03896685), and in the trials’ pharmacokinetic and pharmacodynamic (PK/PD) sub-study (PandrTB, NCT03827811). He is supported by an NIH/NIAID Mentored Clinical Scientist Research Career Development Award (K08 AI141740) which leverages his role in the trials above to examine the safety, tolerability, and PK/PD of new and repurposed drugs for MDR-TB treatment. Dr. Velasquez also serves as an Investigator in the AIDS Clinical Trials Group’s TB Transformative Science Group. His clinical practice is in the HIV and TB clinics at San Francisco General Hospital.